![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Retreatment of Hepatitis C Virus-infected Patients Who Failed Glecaprevir/Pibrentasvir
|
|
|
AASLD - American Association for the Study of Liver Diseases, The Liver Meeting, November 12-15, 2021
F Weilert1, H Tang2, B Yao3, M Lin4, R Skoien5, SW Paik6, W Xie7, V Morozov8, R Tripathi3, Z Zhang3, M Burroughs3, E Gane9
1Waikato Hospital, Hamilton, WKO, New Zealand; 2Infectious Diseases Center, West China Hospital and Sichuan University, Chengdu, China; 3AbbVie Inc, North Chicago, IL, USA; 4Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; 5Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, QLD, Australia; 6South Korea Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 7Beijing Di Tan Hospital, Capital Medical University, Beijing, China; 8Hepatolog, LLC, Samara, Russian Federation; 9New Zealand Liver Transplant Unit, University of Auckland, AUK, New Zealand
![1112211](../images/111221/111221-6/1112211.gif)
![1112212](../images/111221/111221-6/1112212.gif)
![1112213](../images/111221/111221-6/1112213.gif)
![1112214](../images/111221/111221-6/1112214.gif)
![1112215](../images/111221/111221-6/1112215.gif)
![1112216](../images/111221/111221-6/1112216.gif)
![1112217](../images/111221/111221-6/1112217.gif)
![1112218](../images/111221/111221-6/1112218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|